“First and foremost, it’s about the patient. Then, the past: What’s gone before to support what’s underway right now. Then, the future: the pipeline.”
Ann Leen, PhD, co-founded and serves as Chief Scientific Officer of AlloVir. For more than 20 years, Dr. Leen has led innovative discovery and translational research focused on developing novel T cell-based therapies. Her research has enabled multiple cell therapy programs to move from bench to bedside. She is currently the principal investigator (PI) on 5 investigator-initiated Investigational New Drug (IND) studies and over the past 10 years has served as PI on more than 10 clinical trials using “first in man” cell therapies for patients.
In addition to her role at AlloVir, Dr. Leen continues to serve as Professor in the Department Pediatrics at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, where she has held various faculty positions since 2005. She is senior or co-author on more than 90 publications and a named inventor on 14 published patents.
Ann received her BS in Biochemistry at the University of College Cork in Cork, Ireland and her PhD in Immunology at the CRC Institute for Cancer Studies in Birmingham, UK.
